Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies

Abdulhameed Alhazmi; Carel W. le Roux

doi:10.3389/fendo.2026.1788698

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies

Abdulhameed Alhazmi
, Carel W. le Roux

Research output: Contribution to journal › Opinion › peer-review

2 Downloads (Pure)

Original language	English
Article number	1788698
Pages (from-to)	1-5
Number of pages	5
Journal	Frontiers in Endocrinology
Volume	17
Early online date	3 Mar 2026
DOIs	https://doi.org/10.3389/fendo.2026.1788698
Publication status	Published online - 3 Mar 2026

Bibliographical note

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

GLP1
nausea & vomiting
obesity
semaglutide
side effect
tirzepatide
GLP 1
Obesity
Nausea & Vomiting
Glp 1
Semaglutide
Tirzepatide
Side effect

Access to Document

10.3389/fendo.2026.1788698

fendo-17-1788698Final published version, 377 KBLicence: CC BY

Cite this

@article{b442949e0cd843fa9c724522bc390ceb,

title = "Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies",

keywords = "GLP1, nausea \& vomiting, obesity, semaglutide, side effect, tirzepatide, GLP 1, Obesity, Nausea \& Vomiting, Glp 1, Semaglutide, Tirzepatide, Side effect",

author = "Abdulhameed Alhazmi and \{le Roux\}, \{Carel W.\}",

note = "{\textcopyright}2026 Alhazmi and le Roux. ",

year = "2026",

month = mar,

day = "3",

doi = "10.3389/fendo.2026.1788698",

language = "English",

volume = "17",

pages = "1--5",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers",

}

TY - JOUR

T1 - Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies

AU - Alhazmi, Abdulhameed

AU - le Roux, Carel W.

PY - 2026/3/3

Y1 - 2026/3/3

KW - GLP1

KW - nausea & vomiting

KW - obesity

KW - semaglutide

KW - side effect

KW - tirzepatide

KW - GLP 1

KW - Obesity

KW - Nausea & Vomiting

KW - Glp 1

KW - Semaglutide

KW - Tirzepatide

KW - Side effect

UR - https://www.scopus.com/pages/publications/105032872369

U2 - 10.3389/fendo.2026.1788698

DO - 10.3389/fendo.2026.1788698

M3 - Opinion

SN - 1664-2392

VL - 17

SP - 1

EP - 5

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 1788698

ER -

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Cite this